Thermo Fisher Scientific (TMO) Announces Fiscal Q1 2026 Results

robot
Abstract generation in progress

Thermo Fisher Scientific (NYSE: TMO) announced strong financial results for fiscal Q1 2026, with revenue rising 6% to $11.01 billion and GAAP diluted EPS increasing 11% to $4.43. The company also introduced several innovative products during the quarter, including new cryo-TEM, mass spectrometer, XRF analyzer, and cell therapy manufacturing systems. TMO is recognized as a top stem cell therapy stock, but the article suggests that other AI stocks might offer higher returns.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin